Answers are grounded in this paper and cite their sources.
As is well-known, the process of developing new drugs is extremely expensive, whereas drug repurposing represents a promising approach to augment the efficiency of new drug development. While this method can indeed spare us from expensive drug toxicity and safety experiments, it still demands a substantial amount of time to carry out precise efficacy experiments for specific diseases, thereby consuming a significant quantity of resources. Therefore, if we can prescreen potential other indications for selected drugs, it could result in substantial cost savings. In light of this, this paper introduces a drug repurposing recommendation model called MRNDR, which stands for
No takes yet. Share an insight, caveat, or question.
Feng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: